A functional matrix metalloproteinase (MMP)-9 polymorphism modifies plasma MMP-9 levels in subjects environmentally exposed to mercury

Altieri, 2003, Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure, Eur J Clin Invest, 33, 648, 10.1046/j.1365-2362.2003.01187.x Barbosa, 2006, Matrix metalloproteinase-9 activity in plasma correlates with plasma and whole blood lead concentrations, Basic Clin Pharmacol Toxicol, 98, 559, 10.1111/j.1742-7843.2006.pto_392.x Belo, 2009, Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents, Clin Biochem, 42, 984, 10.1016/j.clinbiochem.2009.03.025 Belvisi, 2003, The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs?, Inflamm Res, 52, 95, 10.1007/s000110300020 Berglund, 2005, Inter-individual variations of human mercury exposure biomarkers: a cross-sectional assessment, Environ Health, 4, 20, 10.1186/1476-069X-4-20 Blankenberg, 2003, Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease, Circulation, 107, 1579, 10.1161/01.CIR.0000058700.41738.12 Boffetta, 2001, Mortality from cardiovascular diseases and exposure to inorganic mercury, Occup Environ Med, 58, 461, 10.1136/oem.58.7.461 Bonnema, 2007, Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs), J Card Fail, 13, 530, 10.1016/j.cardfail.2007.04.010 Budtz-Jorgensen, 2004, Association between mercury concentrations in blood and hair in methylmercury-exposed subjects at different ages, Environ Res, 95, 385, 10.1016/j.envres.2003.11.001 Castro, 2008, Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats, Atherosclerosis, 198, 320, 10.1016/j.atherosclerosis.2007.10.011 Castro, 2010, Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling, Matrix Biol, 29, 194, 10.1016/j.matbio.2009.11.005 Clarkson, 2006, The toxicology of mercury and its chemical compounds, Crit Rev Toxicol, 36, 609, 10.1080/10408440600845619 de Marco, 2009, Environmental exposure to methylmercury is associated with a decrease in nitric oxide production, Basic Clin Pharmacol Toxicol, 106, 411, 10.1111/j.1742-7843.2009.00519.x Demacq, 2006, Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma MMP-9 activity in healthy subjects, Clin Chim Acta, 365, 183, 10.1016/j.cca.2005.08.017 Demacq, 2008, Inverse relationship between markers of nitric oxide formation and plasma matrix metalloproteinase-9 levels in healthy volunteers, Clin Chim Acta, 394, 72, 10.1016/j.cca.2008.04.008 Demacq, 2008, Functional polymorphisms in the promoter of the matrix metalloproteinase-9 (MMP-9) gene are not linked with significant plasma MMP-9 variations in healthy subjects, Clin Chem Lab Med, 46, 57, 10.1515/CCLM.2008.014 Demacq, 2009, A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients, Pharmacogenomics J, 9, 265, 10.1038/tpj.2009.13 Fiotti, 2005, MMP-9 microsatellite polymorphism: association with the progression of intima-media thickening and constrictive remodeling of carotid atherosclerotic plaques, Atherosclerosis, 182, 287, 10.1016/j.atherosclerosis.2005.01.009 Fiotti, 2006, MMP-9 microsatellite polymorphism and susceptibility to carotid arteries atherosclerosis, Arterioscler Thromb Vasc Biol, 26, 1330, 10.1161/01.ATV.0000219233.31702.c9 Garvin, 2008, Circulating matrix metalloproteinase-9 is associated with cardiovascular risk factors in a middle-aged normal population, PLoS One, 3, e1774, 10.1371/journal.pone.0001774 Gerlach, 2005, Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities, Anal Biochem, 344, 147, 10.1016/j.ab.2005.04.038 Gerlach, 2007, Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma, Clin Biochem, 40, 119, 10.1016/j.clinbiochem.2006.10.007 Goldberg, 1992, Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin, J Biol Chem, 267, 4583, 10.1016/S0021-9258(18)42873-6 Goncalves, 2009, Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome, Clin Chim Acta, 403, 173, 10.1016/j.cca.2009.02.013 Goulle, 2005, Metal and metalloid multi-elementary ICP-MS validation in whole blood, plasma, urine and hair. Reference values, Forensic Sci Int, 153, 39, 10.1016/j.forsciint.2005.04.020 Guallar, 2002, Mercury, fish oils, and the risk of myocardial infarction, N Engl J Med, 347, 1747, 10.1056/NEJMoa020157 Jacob-Ferreira, 2009, Mercury exposure increases circulating net matrix metalloproteinase (MMP)-2 and MMP-9 activities, Basic Clin Pharmacol Toxicol, 105, 281, 10.1111/j.1742-7843.2009.00443.x Jones, 2003, Functional matrix metalloproteinase-9 polymorphism (C-1562T) associated with abdominal aortic aneurysm, J Vasc Surg, 38, 1363, 10.1016/S0741-5214(03)01027-9 Koh, 2008, A close relationship between functional polymorphism in the promoter region of matrix metalloproteinase-9 and acute myocardial infarction, Int J Cardiol, 127, 430, 10.1016/j.ijcard.2007.04.107 Lamblin, 2002, Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease, J Am Coll Cardiol, 40, 43, 10.1016/S0735-1097(02)01909-5 Lynch, 2004, Novel diagnostic test for acute stroke, Stroke, 35, 57, 10.1161/01.STR.0000105927.62344.4C Maeda, 2001, Dinucleotide repeat polymorphism of matrix metalloproteinase-9 gene is associated with diabetic nephropathy, Kidney Int, 60, 1428, 10.1046/j.1523-1755.2001.00945.x Marcaccini, 2009, Circulating matrix metalloproteinase-8 (MMP-8) and MMP-9 are increased in chronic periodontal disease and decrease after non-surgical periodontal therapy, Clin Chim Acta, 409, 117, 10.1016/j.cca.2009.09.012 Martinez, 2006, Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension, J Cardiovasc Pharmacol, 47, 117, 10.1097/01.fjc.0000196241.96759.71 Martins-Oliveira, 2009, Different circulating metalloproteinases profiles in women with migraine with and without aura, Clin Chim Acta, 408, 60, 10.1016/j.cca.2009.07.008 Mergler, 2007, Methylmercury exposure and health effects in humans: a worldwide concern, Ambio, 36, 3, 10.1579/0044-7447(2007)36[3:MEAHEI]2.0.CO;2 Morgan, 2003, Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease, J Mol Med, 81, 321, 10.1007/s00109-003-0441-z Morimoto, 1997, Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinases, and extracellular matrix mRNA following exposure to mineral fibers and cigarette smoke in vivo, Environ Health Perspect, 105, 1247 Ning, 2007, Cigarette smoke stimulates matrix metalloproteinase-2 activity via EGR-1 in human lung fibroblasts, Am J Respir Cell Mol Biol, 36, 480, 10.1165/rcmb.2006-0106OC Paczek, 2008, Trypsin, elastase, plasmin and MMP-9 activity in the serum during the human ageing process, Age Ageing, 37, 318, 10.1093/ageing/afn039 Palei, 2008, Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension, Clin Biochem, 41, 875, 10.1016/j.clinbiochem.2008.04.015 Palei, 2010, Matrix metalloproteinase (MMP)-9 genotypes and haplotypes in preeclampsia and gestational hypertension, Clin Chim Acta, 411, 874, 10.1016/j.cca.2010.03.002 Palmer, 2006, Determination of lead, cadmium and mercury in blood for assessment of environmental exposure: a comparison between inductively coupled plasma-mass spectrometry and atomic absorption spectrometry, Spectrochim Acta Part B At Spectrosc, 61, 980, 10.1016/j.sab.2006.09.001 Passos, 2008, Human mercury exposure and adverse health effects in the Amazon: a review, Cad Saude Publica, 24, s503, 10.1590/S0102-311X2008001600004 Passos, 2008, Daily mercury intake in fish-eating populations in the Brazilian Amazon, J Expo Sci Environ Epidemiol, 18, 76, 10.1038/sj.jes.7500599 Peters, 1999, Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm, Stroke, 30, 2612, 10.1161/01.STR.30.12.2612 Pollanen, 2001, Coronary artery complicated lesion area is related to functional polymorphism of matrix metalloproteinase 9 gene: an autopsy study, Arterioscler Thromb Vasc Biol, 21, 1446, 10.1161/hq0901.095545 Ra, 2007, Control of matrix metalloproteinase catalytic activity, Matrix Biol, 26, 587, 10.1016/j.matbio.2007.07.001 Raitio, 2005, Levels of matrix metalloproteinase-2, -9 and -8 in the skin, serum and saliva of smokers and non-smokers, Arch Dermatol Res, 297, 242, 10.1007/s00403-005-0597-1 Registry AfTSaD. Toxicological Profile for Mercury. In: Service USDoHaHSPH, editor, Atlanta, GA, 1999. Salonen, 2000, Mercury accumulation and accelerated progression of carotid atherosclerosis: a population-based prospective 4-year follow-up study in men in eastern Finland, Atherosclerosis, 148, 265, 10.1016/S0021-9150(99)00272-5 Samnegard, 2009, Gender specific associations between matrix metalloproteinases and inflammatory markers in post myocardial infarction patients, Atherosclerosis, 202, 550, 10.1016/j.atherosclerosis.2008.05.050 Sandrim, 2010, eNOS haplotypes affect the responsiveness to antihypertensive therapy in preeclampsia but not in gestational hypertension, Pharmacogenomics J, 10, 40, 10.1038/tpj.2009.38 Sanger, 1992, DNA sequencing with chain-terminating inhibitors. 1977, Biotechnology, 24, 104 Segura-Valdez, 2000, Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD, Chest, 117, 684, 10.1378/chest.117.3.684 Shimajiri, 1999, Shortened microsatellite d(CA)21 sequence down-regulates promoter activity of matrix metalloproteinase 9 gene, FEBS Lett, 455, 70, 10.1016/S0014-5793(99)00863-7 Souza-Tarla, 2005, Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities, Clin Biochem, 38, 410, 10.1016/j.clinbiochem.2005.02.010 Sundstrom, 2006, Circulating biomarkers of extracellular matrix remodeling and risk of atherosclerotic events, Curr Opin Lipidol, 17, 45, 10.1097/01.mol.0000203891.34890.b5 Tan, 2007, Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension, Hypertens Res, 30, 959, 10.1291/hypres.30.959 Timms, 2002, Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders?, QJM, 95, 787, 10.1093/qjmed/95.12.787 Uzuelli, 2008, Severity dependent increases in circulating cardiac troponin I and MMP-9 concentrations after experimental acute pulmonary thromboembolism, Clin Chim Acta, 388, 184, 10.1016/j.cca.2007.11.001 Van den Steen, 2002, Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9), Crit Rev Biochem Mol Biol, 37, 375, 10.1080/10409230290771546 Virtanen, 2005, Mercury, fish oils, and risk of acute coronary events and cardiovascular disease, coronary heart disease, and all-cause mortality in men in eastern Finland, Arterioscler Thromb Vasc Biol, 25, 228, 10.1161/01.ATV.0000150040.20950.61 Virtanen, 2007, Mercury as a risk factor for cardiovascular diseases, J Nutr Biochem, 18, 75, 10.1016/j.jnutbio.2006.05.001 Woessner, 1998, The matrix metalloproteinase family, 1 Wright, 2007, Cigarette smoke upregulates pulmonary vascular matrix metalloproteinases via TNF-alpha signaling, Am J Physiol Lung Cell Mol Physiol, 292, L125, 10.1152/ajplung.00539.2005 Zhang, 1999, Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis, Circulation, 99, 1788, 10.1161/01.CIR.99.14.1788 Zouridakis, 2004, Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris, Circulation, 110, 1747, 10.1161/01.CIR.0000142664.18739.92